Pattern and Management of Vaginal Bleeding Complications, Especially Hypermenorrhea, with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119)
نویسندگان
چکیده
منابع مشابه
Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry.
AIMS Patients receiving novel oral anticoagulants (NOACs) frequently undergo interventional procedures. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without heparin bridging. However, outcome data for this approach are lacking. We evaluated the peri-interventional NOAC management in unselected patients from daily care. METHODS AND RESULTS Effectivene...
متن کاملRates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.
Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism, but little is known about rivaroxaban-related bleeding complications in daily care. Using data from a prospective, noninterventional oral anticoagulation registry of daily care patients (Dresden NOAC registry), we analyzed rates, management, and outcome of rivaroxaba...
متن کاملBleeding complications from the direct oral anticoagulants
BACKGROUND Direct oral anticoagulants (DOACs) are now standard of care for the management of thromboembolic risk. A prevalent issue of concern is how to manage direct oral anticoagulant (DOAC)-associated bleeding for which there is no specific antidote available for clinical use. We conducted a retrospective case series to describe the Toronto, Canada multicenter experience with bleeding from d...
متن کاملManagement of bleeding in patients treated with direct oral anticoagulants
BACKGROUND Recently, a new generation of direct-acting oral anticoagulants (DOACs) with a greater specificity towards activated coagulation factors was introduced based on encouraging results for efficacy and safety in clinical studies. An initial limitation of these new drugs was the absence of an adequate strategy to reverse the effect if a bleeding event occurs or an urgent invasive procedur...
متن کاملManagement of Bleeding Complications in Patients on New Oral Anticoagulants
Until recently, the Vitamin K antagonist (VKA) warfarin was the only oral anticoagulant available for clinical use. However, with the US FDA approval of new oral anticoagulants (NOAs) such as dabigatran, rivaroxaban and apixaban, there currently exist several choices. With any anticoagulant, bleeding complications are anticipated and require well defined management guidelines. Unlike warfarin, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2015
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v126.23.1131.1131